Moleculin Biotech Announces 45th Enrollee In Phase2B/3 Trial For Annamycin Plus Cytarabine As A Treatment For Relapsed Or Refractory Acute Myeloid Leukemia
Benzinga Newsdesk 7 months ago
News
This milestone triggers the final phase of preparation for the trial's interim 45 subject data unblinding, which remains on track for mid-2026 and represents a potentially defining inflection point for the Company.
This milestone triggers the final phase of preparation for the trial's interim 45 subject data unblinding, which remains on track for mid-2026 and represents a potentially defining inflection point for the Company.